Efficacy and safety of tegileridine for postoperative analgesia in patients undergoing thoracoscopic lung resection

Efficacy and safety of tegileridine for postoperative analgesia in patients undergoing thoracoscopic lung resection: A randomized controlled trial

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2500114530

Enrollment

Unknown

Registered

2025-12-15

Start date

2025-12-15

Completion date

Unknown

Last updated

2026-01-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Postoperative analgesia for patients undergoing thoracoscopic lung resection

Interventions

Sufentanil group:Postoperative analgesic drug use: Sufentanil

Tegileridine group:Postoperative analgesic drug use: tegileridine

Eligibility

Sex/Gender

All

Age

18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. Ages 18 to 70, any gender. 2. BMI 18.5 ~ 28.0 kg/m^2; 3. ASAI ~ ?; 4. Elective thoracoscopic lung resection; 5. The patient or their family has signed the informed consent form.

Exclusion criteria

Exclusion criteria: 1. Severe cardiopulmonary diseases: NYHA class III or higher heart failure, or severe respiratory depression such as oxygen saturation below 90%, acute or severe bronchial asthma, etc.; 2. Severe liver and kidney dysfunction (Child-Pugh class C); 3. Presence of mental disorders and cognitive impairments; 4. Known or suspected gastrointestinal obstruction, including paralytic ileus; 5. History of opioid allergy; 6. History of alcohol or painkiller abuse; 7. History of epilepsy, history of chronic pain; 8. Pregnant or breastfeeding women; 9. Refuse to participate.

Design outcomes

Primary

Measure	Time frame
rest numerical rating scale (NRS) scores at 24h postoperatively;	—

Secondary

Measure	Time frame
Number of postoperative rescue analgesia and dosage;Time of first postoperative PCIA, first remedial analgesia and first getting out of bed;Postoperative 24-hour analgesic pump drug consumption;Postoperative pain management satisfaction score;Incidence of postoperative adverse reactions;coughing NRS scores at 24h postoperatively,rest and coughing NRS scores at 2,4,48 h postoperatively;Number of effective PCIA presses versus actual presses at 24 and 48 hours postoperatively;Postoperative days 1, 2, and 3 delirium diagnosis 3D-CAM scale scores;	—

Measure

Time frame

Number of postoperative rescue analgesia and dosage;Time of first postoperative PCIA, first remedial analgesia and first getting out of bed;Postoperative 24-hour analgesic pump drug consumption;Postoperative pain management satisfaction score;Incidence of postoperative adverse reactions;coughing NRS scores at 24h postoperatively,rest and coughing NRS scores at 2,4,48 h postoperatively;Number of effective PCIA presses versus actual presses at 24 and 48 hours postoperatively;Postoperative days 1, 2, and 3 delirium diagnosis 3D-CAM scale scores;

—

Countries

China

Contacts

Public ContactLiu Wei

Nanjing Drum Tower Hospital Group Suqian Hospital

13327840909@163.com+86 527 8423 9872

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026